Harbour BioMed
Tracked across 2 events · 13 articles · First seen Jun 10, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Harbour BioMed, a global biopharmaceutical company, announced that the China — National Medical Products Administration (NMPA) of China has accepted its Investigational New Drug (IND) application for HBM7004. HBM7004 is a novel B7H4xCD3 bispecific antibody…
Impact: Harbour BioMed's IND application for HBM7004 has been accepted by the China — National Medical Products Administration (NMPA) of China, which is a positive step towards clinical evaluation in China and could enhance its market position in oncology therapeutics.
Jun 10, 2026 · 7 articles
Business
Harbour BioMed>>> announced the appointment of Dhavalkumar Patel>>> as a Scientific Advisor. Dhavalkumar Patel>>> brings over two decades of experience in therapeutic innovation from roles at Sana Biotechnology>>>, EITC>>>, and Novartis>>>. His expertise is expected…
Impact: Harbour BioMed appointed Dhavalkumar Patel>>> as a Scientific Advisor, which is expected to enhance its immunology pipeline and drug development capabilities.
Jun 12, 2026 · 6 articles
100
Harbour BioMed appointed Scientific Advisor Dhavalkumar PatelHarbour_BioMed appoints...
100
China — National Medical Products Administration accepted IND application Harbour BioMedHarbour BioMed HBM7004 IND...
70
Harbour BioMed developed bispecific antibodyHarbour BioMed HBM7004 IND...
60
United States — Food and Drug Administration cleared IND application Harbour BioMedHarbour BioMed HBM7004 IND...
NEWSDESK
Track Harbour BioMed live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard